Ray Chen, Omega Optics Inc.

Ray Chen is the founder and the CTO of Omega Optics Inc. since its initiation in 2001.  In the past, he served as the CTO, Founder, and Chairman of the Board of Radiant Research, Inc. from 2000 to 2001, where he raised 18 million dollars A-Round funding to commercialize polymer-based photonic devices involving over twenty patents, which were acquired by Finisar in 2002, a publicly traded company in the Silicon Valley (NASDAQ:FNSR).  His research work has been awarded many research grants and contracts from such sponsors as Army, Navy, Air Force, DARPA, MDA, NSA, NSF, DOE, EPA, NIH, NASA, the State of Texas, and private industry.

Ray Chen is also the Keys and Joan Curry/Cullen Trust Endowed Chair at The University of Texas Austin.  Chen is the director of the Nanophotonics and Optical Interconnects Research Lab, at the Microelectronics Research CenterHe received his BS degree in Physics in 1980 from the National Tsing Hua University in Taiwan, his MS degree in physics in 1983, and his PhD degree in Electrical Engineering in 1988, both from the University of California.  His group has published 750 research articles, including over 85 invited papers. He holds over 25 issued patents. He has chaired or been a program-committee member for more than 110 domestic and international conferences organized by IEEE, SPIE (The International Society of Optical Engineering), OSA, and PSC. He has served as an editor, co-editor or coauthor for over twenty books.  Chen has also served as a consultant for various federal agencies and private companies and delivered numerous invited talks to professional societies. Chen is a Fellow of IEEE, OSA, and SPIE.



On-chip Bio-sensing System using Silicon Nanophotonic Devices


Ray T. Chen, Swapnajit chakravarty and Naimei Tang

Omega Optics

8500 Shoel Creek Blvd

Austin, TX 78757


In this presentation, the unique features of our devices for early cancer detection are presented with unprecedented sensitivity without compromising specificity.  Slow light photonic devices on silicon CMOS chip is employed as the platform with integrated microfluidic channels capable of analyzing 16 different biomarkers are in the process of realization.  The presented biosensing system is an open system suitable for any biomarker detection and drug screening.  At present time, we have detected data for lung cancer and breast cancer.  Pancreatic cancer biomarkers from real patient blood sample are under testing right now. 

From the business point of view, we are currently using a European foundry for wafer scale fabrication to provide a large number of silicon sensor chips.  It will be good if federal government agencies can help small companies to provide domestic foundry for this purpose with cost-effectiveness.  We have 10 patents granted for this technology.  We are in the process of building prototypes that can be used for research institutes without FDA approval which will be time and cash consuming.  Further exploration of outside private investors will also be engaged when we have some sales which will boost the valuation of the company.  We also are in the process of developing a portable, smartphone compatible, silicon chip based photonic crystal microarray for the high throughput mutiplexed detection of antibiotics and antifungals simultaneously at the same instant of time in blood and serum. Two drugs, vancomycin and gentamicin are detected simultaneously with specificity over a wide dynamic range of concentration from 1e-3M to 1e-8M.

Further issues of concerns such as traversing the “valley of death” and future system manufacturing, to name a few, will be presented in the meeting


(Updated Sept. 2014)